NAB 001
Alternative Names: DRL-NAB-P2; NAB001Latest Information Update: 03 Jun 2015
At a glance
- Originator Promius Pharma
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Onychomycosis
Most Recent Events
- 25 Jul 2011 Phase-III development is ongoing in USA